Assenagon Asset Management
SGMO

Assenagon Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Assenagon Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-293,949
Closed -$193K – 1229
2025
Q1 		$193K Buy
+293,949
New +$311K ﹤0.01% 1116
2024
Q1 		– Sell
-1,033,322
Closed -$561K – 1470
2023
Q4 		$561K Buy
1,033,322
+129,811
+14% +$59.8K ﹤0.01% 1238
2023
Q3 		$542K Sell
903,511
-36
-0% -$39 ﹤0.01% 1184
2023
Q2 		$1.17M Hold
903,547
– – ﹤0.01% 929
2023
Q1 		$1.59M Buy
903,547
+39,107
+5% +$112K 0.01% 917
2022
Q4 		$2.71M Sell
864,440
-8,544
-1% -$33.2K 0.01% 712
2022
Q3 		$4.28M Sell
872,984
-39
-0% -$200 0.02% 524
2022
Q2 		$3.61M Hold
873,023
– – 0.01% 643
2022
Q1 		$5.07M Buy
873,023
+860,547
+6,898% +$5.12M 0.01% 530
2021
Q4 		$94K Buy
+12,476
New +$108K ﹤0.01% 1398
2020
Q4 		– Sell
-332,611
Closed -$3.14M – 1231
2020
Q3 		$3.14M Buy
+332,611
New +$3.6M 0.02% 475

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Assenagon Asset Management's SGMO Position: Q2 2025 in Review

Assenagon Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 293,949 shares — an estimated $193K sold.

Assenagon Asset Management first reported a position in SGMO in Q3 2020 and held it in 11 quarters. The position peaked at $5.07M in Q1 2022. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Assenagon Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 293,949 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $193K.
  • Assenagon Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2020 and held it in 11 quarters.
  • Assenagon Asset Management's SANGAMO THERAPEUTICS INC position peaked at $5.07M in Q1 2022.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Assenagon Asset Management's 13F filing for Q2 2025, filed 11 Jul 2025.